Tivantinib

Tivantinib

Systematic (IUPAC) name
(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione
Clinical data
Routes of administration	Oral
Legal status	Investigational
Identifiers
CAS Number	905854-02-6
ATC code	none
PubChem	CID 11494412
ChemSpider	9669218
ChEMBL	CHEMBL2103882
Synonyms	ARQ197; ARQ-197
Chemical data
Formula	C23H19N3O2
Molar mass	369.42 g/mol
SMILES C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65
InChI InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2, (H,25,27,28)/t19-,20-/m0/s1 Key:UCEQXRCJXIVODC-PMACEKPBSA-N

Tivantinib (ARQ197; by Arqule, Inc.) is an experimental anti-cancer drug. It is a bisindolylmaleimide that binds to the dephosphorylated MET kinase in vitro. Tivantinib is being tested clinically as a highly selective MET inhibitor.^[1] However, the mechanism of action of tivantinib is still unclear.

Tivantinib displays cytotoxic activity via molecular mechanisms that are independent from its ability to bind MET.^[2]

Possible applications include non-small-cell lung carcinoma, hepatocellular carcinoma, and oesophageal cancer.^[3]

References

1. "ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko Kirin in Japan - WSJ.com". online.wsj.com. Retrieved 2014-02-09.
2. Basilico, C; Pennacchietti, S; Vigna, E; Chiriaco, C; Arena, S; Bardelli, A; Valdembri, D; Serini, G; Michieli, P (2013). "Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET". Clinical Cancer Research 19 (9): 2381–92. doi:10.1158/1078-0432.CCR-12-3459. PMID 23532890.
3. H. Spreitzer (24 November 2014). "Neue Wirkstoffe – Tivantinib". Österreichische Apothekerzeitung (in German) (24/2014): 30.